PLYX
Polaryx Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$2.00
+0.50%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−12.9x
Market Cap
$99.69M
MomentumView details →
1D Return
+0.50%
YTD Return
—
RSI (14)
43.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−12.9x
Market Cap
$99.69M
RSI (14)
43.0
MomentumView details →
1D Return
+0.50%
YTD Return
—
Similar companies
Latest newsMore news →
Polaryx Therapeutics announced it is on track to initiate its SOTERIA Phase 2 basket trial for PLX-200 in the fourth quarter of 2026, following FDA authorization, CRO engagement, and Fast Track Designation across all four planned indications.11d agoPolaryx Therapeutics, Inc. signed a $10 million PIPE private placement financing, issuing 2,502,696 shares of common stock at approximately $4.00 per share.100d ago